Editor's Note:
The FTC recently provided further fuel for industry watchers worried about the impact private equity could have on healthcare. For those who missed it, Welsh Carson has purportedly built a monopoly in anesthesiology and may be trying to do the same in imaging. The NYC PE firm has vehemently denied these claims while emphasizing that its radiology investment has nothing to do with its work in anesthesiology. But the lawsuit provides an interesting additional point of conversation as providers closely watch to see how private equity reshapes the specialty for the long term. Time will tell whether the FTC’s action is a turning point in the industry or just a speed bump in the road. As always, thanks for reading and enjoy the month ahead.
—Marty Stempniak, Editor
Editor's Note:
The FTC recently provided further fuel for industry watchers worried about the impact private equity could have on healthcare. For those who missed it, Welsh Carson has purportedly built a monopoly in anesthesiology and may be trying to do the same in imaging. The NYC PE firm has vehemently denied these claims while emphasizing that its radiology investment has nothing to do with its work in anesthesiology. But the lawsuit provides an interesting additional point of conversation as providers closely watch to see how private equity reshapes the specialty for the long term. Time will tell whether the FTC’s action is a turning point in the industry or just a speed bump in the road. As always, thanks for reading and enjoy the month ahead.
—Marty Stempniak, Editor